Mereo BioPharma Group (NASDAQ:MREO – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Mereo BioPharma Group to related businesses based on the strength of its earnings, dividends, institutional ownership, profitability, risk, valuation and analyst recommendations.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Mereo BioPharma Group and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mereo BioPharma Group | 2 | 3 | 3 | 0 | 2.12 |
| Mereo BioPharma Group Competitors | 9959 | 15361 | 45766 | 1602 | 2.54 |
Mereo BioPharma Group presently has a consensus target price of $1.67, indicating a potential upside of 541.03%. As a group, “Biotechnology” companies have a potential upside of 114.69%. Given Mereo BioPharma Group’s higher probable upside, analysts clearly believe Mereo BioPharma Group is more favorable than its competitors.
Valuation & Earnings
This table compares Mereo BioPharma Group and its competitors top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Mereo BioPharma Group | $500,000.00 | -$41.88 million | -6.50 |
| Mereo BioPharma Group Competitors | $750.67 million | $10.42 million | -17.98 |
Mereo BioPharma Group’s competitors have higher revenue and earnings than Mereo BioPharma Group. Mereo BioPharma Group is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares Mereo BioPharma Group and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mereo BioPharma Group | N/A | -84.62% | -71.44% |
| Mereo BioPharma Group Competitors | -12,519.20% | -215.47% | -31.42% |
Risk & Volatility
Mereo BioPharma Group has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500. Comparatively, Mereo BioPharma Group’s competitors have a beta of -1.84, suggesting that their average stock price is 284% less volatile than the S&P 500.
Institutional & Insider Ownership
62.8% of Mereo BioPharma Group shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 6.5% of Mereo BioPharma Group shares are held by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Mereo BioPharma Group competitors beat Mereo BioPharma Group on 7 of the 13 factors compared.
About Mereo BioPharma Group
Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases and cancer. Established in 2015 and based in the United Kingdom, the company advances drug candidates that it has acquired or licensed from other pharmaceutical developers. Its rare-disease programs include setrusumab, an investigational antibody being developed for osteogenesis imperfecta, and alvelestat, an investigational oral drug being studied for lung disease associated with alpha-1 antitrypsin deficiency.
Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with MarketBeat.com's FREE daily email newsletter.
